Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 Shares of Company Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Friday, November 13th. The stock was sold at an average price of $100.38, for a total transaction of $2,007,600.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $77,069,756.40. This represents a 2.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

  • On Monday, November 16th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $98.38, for a total transaction of $1,967,600.00.
  • On Tuesday, October 6th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $109.58, for a total transaction of $2,191,600.00.
  • On Thursday, October 8th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $109.40, for a total transaction of $2,188,000.00.
  • On Wednesday, September 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $107.43, for a total transaction of $2,148,600.00.
  • On Friday, September 11th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $107.24, for a total transaction of $2,144,800.00.
  • On Tuesday, August 18th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $104.18, for a total transaction of $2,083,600.00.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO traded down $3.77 during midday trading on Monday, hitting $96.50. The company’s stock had a trading volume of 2,088,290 shares, compared to its average volume of 2,352,912. The company has a debt-to-equity ratio of 13.50, a quick ratio of 3.60 and a current ratio of 3.88. Halozyme Therapeutics, Inc. has a 1-year low of $61.22 and a 1-year high of $134.00. The firm’s fifty day moving average price is $114.29 and its 200-day moving average price is $85.63. The firm has a market cap of $11.00 billion, a P/E ratio of 18.07, a P/E/G ratio of 0.38 and a beta of 0.92.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.09. The firm had revenue of $492.97 million for the quarter, compared to analyst estimates of $491.63 million. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 751.81%. Halozyme Therapeutics’s quarterly revenue was up 39.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.72 earnings per share. On average, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 8.34 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Wells Fargo & Company upped their target price on Halozyme Therapeutics from $95.00 to $110.00 and gave the company an “equal weight” rating in a report on Friday, November 6th. Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b)” rating to a “buy (b+)” rating in a research report on Monday, November 9th. Citizens Jmp raised their price target on Halozyme Therapeutics from $93.00 to $149.00 and gave the stock a “market outperform” rating in a report on Friday, November 6th. Stifel Nicolaus set a $130.00 price objective on Halozyme Therapeutics in a research report on Friday, October 16th. Finally, Leerink Partners lowered Halozyme Therapeutics from an “outperform” rating to a “hold” rating and boosted their price objective for the company from $110.00 to $117.00 in a research report on Friday, November 6th. Seven analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Hold” and a consensus target price of $108.18.

Read Our Latest Analysis on HALO

Institutional Trading of Halozyme Therapeutics

A number of large investors have recently modified their holdings of HALO. Bank of America Corp DE bought a new position in Halozyme Therapeutics in the 2nd quarter worth about $214,504,000. William Blair Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at approximately $196,540,000. Congress Asset Management Co. increased its stake in shares of Halozyme Therapeutics by 85.6% in the third quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock valued at $251,890,000 after purchasing an additional 1,052,509 shares during the period. First Trust Advisors LP raised its holdings in shares of Halozyme Therapeutics by 28.3% during the third quarter. First Trust Advisors LP now owns 1,817,824 shares of the biopharmaceutical company’s stock valued at $200,688,000 after buying an additional 400,761 shares during the last quarter. Finally, Royal London Asset Management Ltd. raised its holdings in shares of Halozyme Therapeutics by 12.4% during the second quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company’s stock valued at $141,732,000 after buying an additional 200,262 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

(Get Free Report)

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Recommended Stories

Insider Buying and Selling by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.